PubMed Health⌕ Search

Biomedical subjects

W W Owen

Publications and source records attributed to W W Owen.

6 recordsLinked to original sources

Data quality assurance, monitoring, and reporting.

In conclusion, the quality assurance and monitoring program is an integral and continuing part of study operations. A system must be devised and implemented by the coordinating center investigators, with the endorsement of the study leadership and support of the field site and resource center personnel. Proactive mechanisms for promoting high-quality data acquisition and reporting must be implemented. Data quality monitoring must address the entire process by which the data are gathered, transmitted, stored, and analyzed. Data quality should be monitored continually, with summary reports prepared and distributed to the study leadership. Appropriate training and certification enhance data quality, and site visits allow data collection and storage processes to be observed directly. The quality assurance and monitoring system must be documented. It should be flexible enough so that new means of quality assurance or monitoring can be added when necessary during the course of the study. At the completion of the study, quality monitoring results should be summarized in a final report regarding the level of quality achieved by the study investigators and personnel. Finally, for a quality assurance and monitoring program to be successful, the coordinating center investigators and personnel must provide prompt feedback and suggestions for corrective action whenever a data quality problem is discovered. This need can be met only when the coordinating center staff understand data quality goals and are up to date with all phases of data management and reporting. Delays in initiating any stage of data management and quality monitoring may result in uncorrectable data problems. Thus, knowledgeable and efficient coordinating center personnel are essential to achieving good data quality studywide.

Clinical Trials as Topic↗

Sympathetic nervous system function in XYY subjects.

Initial reports of males with the XYY sex chromosome anomaly indicated that these individuals excessively exhibit impulsive, aggressive, and criminal behavior. Central nervous system (CNS) defects, including low intelligence, in certain XYY subjects may be associated with these antisocial behaviors. The sympathetic nervous system (SNS) is activated in stressful conditions of "fight or flight" upon standing up from a supine posture, with physical exercise, and with aggressive behavior. Norepinephrine (NE) is the principal neurotransmitter of the SNS, and plasma levels of NE and dopamine-beta-hydroxylase are indices of SNS function. We questioned the integrity of SNS function in XYY subjects for two reasons: (1) their inferred propensity for aggressive behavior and the association of this behavior with increased NE levels; and (2) their potential for CNS dysfunction, which could be reflected in abnormal SNS regulation by the CNS. In the current study plasma levels of NE in XYY subjects are nonsignificantly higher than in normal volunteers. Additionally, XYY patients have a normal NE half-life indicating normal SNS activity and metabolism. Thus, we are unable to document with confidence any abnormality in SNS function in these XYY subjects.

Adolescent↗

Dermorphin: an opioid peptide from amphibian skin which affects endocrine pancreatic function.

We examined the effect of intravenous injection of the amphibian skin opioid heptapeptide dermorphin on plasma glucose, insulin, glucagon and somatostatin in the rat. Dermorphin in doses ranging from 0.1 to 10 micrograms per animal did not affect plasma insulin or somatostatin-like immunoreactivity (SLI). In contrast, the opiate peptide significantly stimulated plasma glucagon and decreased plasma glucose, both 10 and 30 min following injection. The results suggest an effect of dermorphin on the endocrine pancreas. Since dermorphin has been shown to be present in rat and porcine tissues, it may have a role in the regulation of glucose metabolism.

Animals↗

Growth hormone, prolactin and FSH release by the tachykinin dodecapeptide kassinin in the rat.

The effect of equimolar doses of kassinin, a newly discovered tachykinin dodecapeptide, and substance P on serum growth hormone, prolactin and FSH was examined in adult male Fischer 344 rats. The two peptides were injected intravenously 10 or 30 min prior to blood collection by decapitation. Kassinin in concentrations of 0.3 and 3.0 micrograms/100 g B.W., potently stimulated release of growth hormone. Both kassinin and substance P decreased prolactin at the lowest dose. An increase of serum prolactin above control values by both peptides was observed at the highest dose administered. However, this increase with the highest dose depended on the time of blood collection. Serum FSH was increased only by injection of the highest dose of kassinin or substance P. These results demonstrate that kassinin and substance P have similar effects on the secretion of these hormones. The findings provide further evidence for an involvement of peptidergic neurons in the regulation of pituitary function. Kassinin, if present in central and peripheral neurons of the mammalian central and autonomic nervous system and in the cells of the diffuse neuroendocrine system, could function as a neuropeptide.

Animals↗